Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2025, Vol. 57 ›› Issue (2): 272-276. doi: 10.19723/j.issn.1671-167X.2025.02.008

Previous Articles     Next Articles

Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection

Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG*()   

  1. Department of Vascular Surgery, Peking University People's Hospital, Beijing 100044, China
  • Received:2021-09-13 Online:2025-04-18 Published:2025-04-12
  • Contact: Xiaoming ZHANG E-mail:rmyyxgwk@163.com
  • Supported by:
    Peking University People's Hospital Research And Development Funds(RDJP2023-14)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the effect of intraoperative blood salvage autotransfusion on local recurrence and long-term metastasis of patients after carotid body tumor resection. Methods: We retrospectively reviewed a consecutive series of 61 patients undergoing elective carotid body tumor resection from August 2009 to December 2020. Among them, 14 received intraoperative blood salvage autotransfusion (autotrasfusion group) and 47 did not (non-autotransfusion). Data of general information, surgical status and postoperative follow-up results were collected. Results: The proportion of Shamblin Ⅲ in the autotransfusion group was 85.7%, which was significantly higher than 31.9% in the non-autotransfusion group (P=0.003). The average operation time of the 14 patients in the autotransfusion group was (264±84) min, intraoperative blood loss was 1 200 (700, 2 700) mL, and autologous blood transfusion was 500 (250, 700) mL. Of these, 8 patients (57%) required concomitant allogeneic blood with 400 (260, 400) mL of allogeneic blood. The average operation time of the 47 patients in the non-autotransfusion group was (153±75) min, and the intraoperative blood loss was 300 (100, 400) mL. Of these, 6 (13%) required allogeneic blood transfusion, and 520 (400, 520) mL of allogeneic blood was used. Compared with the non-autotransfusion group, the average operation time in the autologous blood transfusion group was significantly longer (P < 0.001), and the intraoperative blood transfusion volume was larger (P=0.007). Of the 14 patients undergoing autotransfusion, 8 (57%) needed allogeneic blood at the same time; while in the 47 non-autologous transfusion patients, 6 (13%) needed allogeneic blood transfusion. The proportion of autotransfusion group using allogeneic blood at the same time was even higher (P=0.002). The incidence of nerve injury within 30 days after surgery was 29.5%, and there was no significant difference between the two groups. No early deaths occurred. The average follow-up was (76±37) months. One case of local recurrence occurred in the non-autotransfusion group. There was no distant metastasis. There were no tumor-related deaths. The estimated 5-year and 10-year overall survival rates were 96.4% and 83.8%, respectively. There was no significant difference in overall survival between the two groups (P=0.506). Conclusion: The use of intraoperative blood salvage autotransfusion increased no risk of local recurrence and distant metastasis in patients with carotid body tumor, which is safe and effective in carotid body tumor resection.

Key words: Blood transfusion, autologous, Operative blood salvage, Carotid body tumor, Prognosis

CLC Number: 

  • R457.1

Table 1

Pre- and post-operative test results in patients of carotid body tumor with and without intraoperative blood salvage"

Perioperative test results Patients with intraoperative blood salvage
(n=14)		 Patients without intraoperative blood salvage
(n=47)		 P
White blood cell/(×109/L) Pre-operative 6.4±1.6 6.0±1.2 0.236
Post-operative 10.4±3.3 10.3±3.1 0.896
Hemoglobin/(g/L) Pre-operative 126±21 130±18 0.489
Post-operative 122±16 119±16 0.457
Platelet/(×109/L) Pre-operative 256±66 239±53 0.335
Post-operative 222±79 218±47 0.809
Ka+/(mmol/L) Pre-operative 3.9±0.3 4.0±0.3 0.452
Post-operative 3.8±0.4 3.8±0.3 0.711
Na+/(mmol/L) Pre-operative 140±1.7 140±2.0 0.502
Post-operative 140±2.6 139±3.0 0.295
Creatinine/(mmol/L) Pre-operative 55±15 63±16 0.131
Post-operative 50±10 57±13 0.094
Prothrombin time/s Pre-operative 11.7±1.1 11.2±0.9 0.098
Post-operative 12.4±1.4 12.3±1.4 0.819

Figure 1

Survival analysis and the Kaplan-Meier curve of patients with carotid body tumor using intraoperative blood salvage or not"

1 郭红磊, 贾彦焘. 颈动脉体瘤临床诊疗研究进展[J]. 临床误诊误治, 2021, 34 (3): 108- 112.
doi: 10.3969/j.issn.1002-3429.2021.03.021
2 Moore MG , Netterville JL , Mendenhall WM , et al. Head and neck paragangliomas: An update on evaluation and management[J]. Otolaryngol Head Neck Surg, 2016, 154 (4): 597- 605.
doi: 10.1177/0194599815627667
3 顾光超, 郑月宏. 颈动脉体瘤的影像学检查及外科治疗进展[J]. 血管与腔内血管外科杂志, 2020, 6 (5): 439- 441.
4 Butt N , Baek WK , Lachkar S , et al. The carotid body and associated tumors: Updated review with clinical/surgical significance[J]. Br J Neurosurg, 2019, 33 (5): 500- 503.
doi: 10.1080/02688697.2019.1617404
5 马赫, 黄燕娟. 术中回收式自体输血技术适应症的应用[J]. 中南医学科学杂志, 2017, 45 (2): 186- 188.
6 李红霞, 韩志强, 钟海燕. 回收式自体输血对肿瘤手术患者预后的影响[J]. 临床输血与检验, 2018, 20 (1): 106- 108.
doi: 10.3969/j.issn.1671-2587.2018.01.036
7 李晶, 蒋京军, 张小明, 等. 颈动脉转流管在复杂颈动脉体瘤手术切除中的应用[J]. 中国普通外科杂志, 2018, 27 (12): 1556- 1562.
doi: 10.7659/j.issn.1005-6947.2018.12.010
8 孔祥国, 李楠, 杨建勇, 等. 术前经导管动脉栓塞对ShamblinⅡ/Ⅲ型颈动脉体瘤切除术的影响[J]. 中山大学学报(医学科学版), 2021, 42 (2): 287- 293.
9 吴朋, 吕国士. 64排CT增强扫描结合血管成像对恶性颈动脉体瘤的诊断价值分析[J]. 中国全科医学, 2013, 16 (3): 354- 356.
10 Mascia D , Esposito G , Ferrante A , et al. Carotid body tumor contemporary management in a high-volume center[J]. J Cardiovasc Surg (Torino), 2020, 61 (4): 459- 466.
11 Gu G , Wu X , Ji L , et al. Proposed modification to the Shamblin's classification of carotid body tumors: A single-center retrospective experience of 116 tumors[J]. Eur J Surg Oncol, 2021, 47 (8): 1953- 1960.
doi: 10.1016/j.ejso.2021.03.244
12 Chen Y , Li Y , Liu J , et al. The clinical characteristics and outcomes of carotid body tumors in Chinese patients: A STROBE-compliant observational study[J]. Medicine (Baltimore), 2020, 99 (3): e18824.
doi: 10.1097/MD.0000000000018824
13 Illuminati G , Pasqua R , Nardi P , et al. Results of resection of carotid body tumors with and without lymphnodes' dissection[J]. Surg Oncol, 2021, 37, 101555.
doi: 10.1016/j.suronc.2021.101555
14 王凤明, 章文成, 张仑. 15例恶性颈动脉体瘤的诊断与治疗[J]. 中国肿瘤临床, 2007, 34 (20): 1185- 1187.
doi: 10.3969/j.issn.1000-8179.2007.20.013
15 陶英杰, 刘经祖, 金锐. 10例恶性颈动脉体瘤之生物学行为分析[J]. 中国肿瘤临床, 2001, 28 (4): 288- 289.
doi: 10.3969/j.issn.1000-8179.2001.04.015
16 廖蓉仙, 徐雪梅, 吕豪. 2010—2018年衢州市回收式自体输血发展与思考[J]. 浙江临床医学, 2020, 22 (3): 461- 462.
17 汪晓晓, 郭建荣. 自体输血在老年患者手术中的应用价值及风险分析[J]. 临床输血与检验, 2021, 23 (2): 259- 262.
doi: 10.3969/j.issn.1671-2587.2021.02.027
18 Kumar N , Ravikumar N , Tan JYH , et al. Current status of the use of salvaged blood in metastatic spine tumour surgery[J]. Neurospine, 2018, 15 (3): 206- 215.
doi: 10.14245/ns.1836140.070
19 聂晓红, 闫瑞琪, 胡强夫, 等. 术中自体血回输对原发性良性脑膜瘤全切术后肿瘤复发的影响[J]. 广东医学, 2020, 41 (9): 956- 958.
20 Bower MR , Ellis SF , Scoggins CR , et al. Phase Ⅱ comparison study of intraoperative autotransfusion for major oncologic procedures[J]. Ann Surg Oncol, 2011, 18 (1): 166- 173.
doi: 10.1245/s10434-010-1228-4
21 Elmalky M , Yasin N , Rodrigues-Pinto R , et al. The safety, efficacy, and cost-effectiveness of intraoperative cell salvage in metastatic spine tumor surgery[J]. Spine J, 2017, 17 (7): 977- 982.
22 Kinnear N , O'Callaghan M , Hennessey D , et al. Intra-operative cell salvage in urological surgery: A systematic review and meta-analysis of comparative studies[J]. BJU Int, 2019, 123 (2): 210- 219.
doi: 10.1111/bju.14373
23 胡晓云, 陈愉, 赵斌江. 等容血液稀释在颈动脉体瘤手术中的应用[J]. 中国输血杂志, 2000, 13 (4): 251- 252.
doi: 10.3969/j.issn.1004-549X.2000.04.014
24 陈述, 潘静. 稀释法自体输血在颈动脉体瘤手术中的应用(附2例报告)[J]. 齐鲁医学杂志, 2003, 18 (1): 84.
[1] Lingfu ZHANG, Ming CHEN, Xiaoyu ZHAO, Gang WANG, Long CUI, Xiaofeng LING, Lixin WANG, Zhi XU, Limei GUO, Chunsheng HOU. Gross classification of gallbladder cancer with primary lesion limited to the gallbladder wall and its correlation with prognosis and precancerous lesions [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 184-189.
[2] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[3] Yaqing MAO, Zhen CHEN, Yao YU, Wenbo ZHANG, Yang LIU, Xin PENG. Impact of type 2 diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1089-1096.
[4] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[5] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[6] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[7] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[8] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[9] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[10] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[11] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[12] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[13] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[14] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[15] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd